North America Cancer Immunotherapy Market to 2032
Overview
The North America Cancer Immunotherapy Market is expected to reach a 152.28 USD Billion by 2032 and is projected to grow at a CAGR of 17.57% from 2025 to 2032.
Revenue, 2024 (USD Billion)
56.05
Forecast, 2032 (USD Billion)
152.28
CAGR, 2024 - 2032
17.57%
Report Coverage
North America
North America Cancer Immunotherapy Market 2018-2032 USD Billion
North America Cancer Immunotherapy Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 56.05 USD Billion
- Projected Market Size (2032): 152.28 USD Billion
- CAGR (2025-2032): 17.57%
Key Findings of North America Cancer Immunotherapy Market
- The North America Cancer Immunotherapy Market was valued at 56.05 USD Billion in 2024.
- The North America Cancer Immunotherapy Market is likely to grow at a CAGR of 17.57% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Intravenous (IV) in Form Segment accounted for the largest share of the market with a revenue of 50.35 USD Billion
- The fastest growing segment Lung Cancer in Application Segment grew Fastest with a CAGR of 24.54% during the forecast period from 2024 to 2032.
North America Cancer Immunotherapy Market Scope
North America Cancer Immunotherapy Market Segmentation & Scope
Application
- Ovarian Cancer
- Cervical Cancer
- Stomach Cancer
- Colorectal Cancer
- Prostate Cancer
- Lung Cancer
- Breast Cancer
- Melanoma
- Multiple Myeloma
- Head & Neck Cancer
- Others
Product
- Oncolytic Virus
- Immunomodulators
- Cell Therapies
- Checkpoint Inhibitors
- Monoclonal Antibodies
- Vaccines
Distribution Channel
- Direct Tenders
- Retail Sales
- Pharmacies
End User
- Hospitals
- Oncology Clinics
- Others
- Homecare
Form
- Intravenous (IV)
- Intramuscular
- Oral
North America Cancer Immunotherapy Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2021 |
| Unit | Revenue in USD Billion |
| Market Value in 2024 | 56.05 USD Billion |
| Market Value in 2032 | 152.28 USD Billion |
| CAGR (2025-2032) | 17.57% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Application,Product,Distribution Channel,End User,Form |
Regional Insights:
-
Leading Market (2024-2032): North America, leading in terms of revenue 56.05 USD Billion in 2024
- Key Country: Canada, leading in terms of revenue with value of 4,960.90 USD Million in 2024.
Segments and Scope
-
North America Cancer Immunotherapy Market to 2032, By Application
- Lung Cancer is the largest segment in North America Cancer Immunotherapy Market to 2032 with a revenue of 9.33 USD Billion in the year 2024.
- Lung Cancer is the Fastest growing segment in North America Cancer Immunotherapy Market to 2032 with a Growth rate of 24.54 % in forecast period 2025-2032.
-
North America Cancer Immunotherapy Market to 2032, By Product
- Checkpoint Inhibitors is the largest segment in North America Cancer Immunotherapy Market to 2032 with a revenue of 36.34 USD Billion in the year 2024.
- Cell Therapies is the Fastest growing segment in North America Cancer Immunotherapy Market to 2032 with a Growth rate of 17.72 % in forecast period 2025-2032.
-
North America Cancer Immunotherapy Market to 2032, By Distribution Channel
- Direct Tenders is the largest segment in North America Cancer Immunotherapy Market to 2032 with a revenue of 35.93 USD Billion in the year 2024.
- Direct Tenders is the Fastest growing segment in North America Cancer Immunotherapy Market to 2032 with a Growth rate of 18.26 % in forecast period 2025-2032.
-
North America Cancer Immunotherapy Market to 2032, By End User
- Hospitals is the largest segment in North America Cancer Immunotherapy Market to 2032 with a revenue of 37.15 USD Billion in the year 2024.
- Hospitals is the Fastest growing segment in North America Cancer Immunotherapy Market to 2032 with a Growth rate of 17.78 % in forecast period 2025-2032.
-
North America Cancer Immunotherapy Market to 2032, By Form
- Intravenous (IV) is the largest segment in North America Cancer Immunotherapy Market to 2032 with a revenue of 50.35 USD Billion in the year 2024.
- Intravenous (IV) is the Fastest growing segment in North America Cancer Immunotherapy Market to 2032 with a Growth rate of 17.69 % in forecast period 2025-2032.
North America Cancer Immunotherapy Market Company Share Analysis
| Company Name |
|
||
| Merck & Co., Inc. | |||
| Janssen Pharmaceuticals, Inc. | |||
| Bristol-Myers Squibb Company | |||
| AstraZeneca | |||
| Gilead Sciences, Inc. | |||
North America Cancer Immunotherapy Market Geographical Sales Distribution, 2018-2032 USD Billion
North America Cancer Immunotherapy Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The North America Cancer Immunotherapy Market is segmented based on Segmentation Application,Product,Distribution Channel,End User,Form.
North America Cancer Immunotherapy Market was valued at USD 56.05(Revenue in USD Billion) in 2021.
North America Cancer Immunotherapy Market is projected to grow at a CAGR of 17.57% during the forecast period of 2024 to 2032.
The Intravenous (IV) segment is expected to dominate the North America Cancer Immunotherapy Market, holding a largest market share of 50.35 USD Billion in 2024
North America Cancer Immunotherapy Market Scope
North America Cancer Immunotherapy Market Segmentation & Scope
Application
- Ovarian Cancer
- Cervical Cancer
- Stomach Cancer
- Colorectal Cancer
- Prostate Cancer
- Lung Cancer
- Breast Cancer
- Melanoma
- Multiple Myeloma
- Head & Neck Cancer
- Others
Product
- Oncolytic Virus
- Immunomodulators
- Cell Therapies
- Checkpoint Inhibitors
- Monoclonal Antibodies
- Vaccines
Distribution Channel
- Direct Tenders
- Retail Sales
- Pharmacies
End User
- Hospitals
- Oncology Clinics
- Others
- Homecare
Form
- Intravenous (IV)
- Intramuscular
- Oral
Frequently Asked Questions
The North America Cancer Immunotherapy Market is segmented based on Segmentation Application,Product,Distribution Channel,End User,Form.
North America Cancer Immunotherapy Market was valued at USD 56.05(Revenue in USD Billion) in 2021.
North America Cancer Immunotherapy Market is projected to grow at a CAGR of 17.57% during the forecast period of 2024 to 2032.
The estimated market value of the North America Cancer Immunotherapy Market for final year is USD 152.28 (USD Billion).
North America Cancer Immunotherapy Market Company Profiling
Frequently Asked Questions
The North America Cancer Immunotherapy Market is segmented based on Segmentation Application,Product,Distribution Channel,End User,Form.
North America Cancer Immunotherapy Market was valued at USD 56.05(Revenue in USD Billion) in 2021.
North America Cancer Immunotherapy Market is projected to grow at a CAGR of 17.57% during the forecast period of 2024 to 2032.
The estimated market value of the North America Cancer Immunotherapy Market for final year is USD 152.28 (USD Billion).
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.